AbbVie’s Allergan Aesthetics Business in FTC Crosshairs Over $550M Soliton Acquisition
AbbVie’s medical aesthetics division Allergan may not get the makeover it was counting on this year if the Federal Trade Commission (FTC) has anything to say about it, Fierce Biotech reports.